STOCKHOLM, Sweden, and VIENNA, Austria, 11.11.2026 — Discovery Evolution FlexCo and AAX Biotech AB today announced a research collaboration to discover and develop bispecific antibody candidates for oncology. The cooperation brings together Discovery Evolution’s capabilities in therapeutic target identification and digital antibody discovery with AAX Biotech’s expertise in antibody and multispecifics engineering and optimization. The companies aim to generate differentiated therapeutic candidates for further preclinical evaluation.
Bispecific antibodies combine two binding specificities in a single molecule, creating opportunities to address cancer biology through complementary mechanisms. Developing these molecules requires suitable antibody building blocks as well as an engineered format with the stability and other molecular properties needed for further development.
Discovery Evolution’s proprietary RedQueen™ discovery engine uses digital directed evolution and computational biophysics to design antibodies against selected targets, with a particular focus on G protein coupled receptors (GPCRs) and other challenging membrane proteins. AAX Biotech contributes expertise in bispecific formats and its proprietary Opti-mAb® technology, designed to improve the yield and stability of single-chain variable fragments (scFvs), which are used as building blocks in many multispecific antibodies.
“Our goal is to turn medically important targets into therapeutic antibody assets,” said Harold P. de Vladár, CEO and Founder of Discovery Evolution. “Working with AAX gives us complementary expertise to translate our antibody discoveries into bispecific candidates. Together, we want to develop oncology molecules with a clear biological rationale and the properties needed to support further development.”
“Identifying a promising antibody binder is an essential starting point – taking that discovery forward requires the right antibody format and molecular properties,” said Daniel X. Johansson, CSO and co-founder of AAX Biotech. “Working with Discovery Evolution allows us to apply our Opti-mAb® technology and antibody engineering expertise to the development of new bispecific antibody candidates for oncology.” The cooperation supports AAX Biotech’s strategy of expanding the use of its Opti-mAb® technology in next-generation antibody development through complementary partnerships, alongside Discovery Evolution’s strategy of building a portfolio of proprietary therapeutic antibody assets. [CK1] The companies intend to evaluate opportunities for further development and partnering as the research progresses.
The collaboration is at the research and proof-of-concept stage. The therapeutic efficacy and safety of any resulting candidates have not been established.
About Discovery Evolution
Discovery Evolution FlexCo is a Vienna-based biotechnology company building a portfolio of therapeutic antibody assets against GPCRs and other complex membrane protein targets. Its proprietary RedQueen™ discovery engine combines digital directed evolution with computational biophysics and focused experimental validation. The company develops antibody programmes across fibrosis, metabolic disease and oncology, with the aim of advancing selected assets through strategic partnerships. Visit discovery-evolution.com to learn more and follow Discovery Evolution on LinkedIn.
About AAX Biotech AB
AAX Biotech AB is a biotech company specializing in next-generation antibody therapeutics. The company offers two unique and proprietary technologies, Seqitope® and Opti-mAb®, that enable high throughput and high-resolution epitope mapping as well as stabilization of single chain variable fragments (scFv) for applications such as bispecific antibodies and CAR-T cells. Both technologies aim to produce better and more effective antibody-based medicines. These innovations position AAX Biotech as a key player in the rapidly growing antibody therapeutics market. AAX Biotech is founded by experts from Karolinska Institutet in Stockholm, Sweden. Visit aaxbiotech.com to learn more and follow AAX Biotech on LinkedIn.
Media contacts
Discovery Evolution FlexCo
Harold P. de Vladár, CEO and Founder
office@discovery-evolution.com
discovery-evolution.com
AAX Biotech AB
Daniel X Johansson, CSO and co-founder
daniel.johansson@aaxbiotech.com
+46 70 490 24 33
aaxbiotech.com